dc.date.accessioned | 2022-02-18T19:33:53Z | |
dc.date.available | 2022-02-18T19:33:53Z | |
dc.date.created | 2021-07-21T15:13:40Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Li, Ruth Gong Napoli, Elisa Jorstad, Ida Sofie Bønsdorff, Tina Bjørnlund Juzeniene, Asta Bruland, Øyvind Sverre Larsen, Roy H. Westrøm, Sara . Calcium carbonate microparticles as carriers of 224Ra: Impact of specific activity in mice with intraperitoneal ovarian cancer. Current Radiopharmaceuticals. 2021, 14(2), 145-153 | |
dc.identifier.uri | http://hdl.handle.net/10852/91106 | |
dc.description.abstract | Background: Patients with advanced-stage ovarian cancer face a poor prognosis because of recurrent peritoneal cavity metastases following surgery and chemotherapy. Alpha-emitters may enable the efficient treatment of such disseminated diseases because of their short range and highly energetic radiation. Radium-224 is a candidate α-emitter due to its convenient 3.6-day half-life, with more than 90% of the decay energy originating from α-particles. However, its inherent skeletal accumulation must be overcome to facilitate intraperitoneal delivery of the radiation dose. Therefore, 224Ra-labeled CaCO3 microparticles have been developed.
Objective: The antitumor effect of CaCO3 microparticles as a carrier for 224Ra was investigated, with an emphasis on the ratio of activity to mass dose of CaCO3, that is, specific activity.
Methods: Nude athymic mice were inoculated intraperitoneally with human ovarian cancer cells (ES-2) and treated with a single intraperitoneal injection of 224Ra-labeled CaCO3 microparticles with varying combinations of mass and activity dose, or cationic 224Ra in solution. Survival and ascites volume at sacrifice were evaluated.
Results: Significant therapeutic effect was achieved for all tested specific activities ranging from 0.4 to 4.6 kBq/mg. Although treatment with a mean activity dose of 1305 kBq/kg of cationic 224Ra prolonged the survival compared with the control, equivalent median survival could be achieved with 224Ra-labeled microparticles with a mean dose of only 420 kBq/kg. The best outcome was achieved with the highest specific activities (2.6 and 4.6 kBq/mg).
Conclusion: Radium-224-labeled CaCO3 microparticles present a promising therapy against cancer dissemination in body cavities. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Calcium carbonate microparticles as carriers of 224Ra: Impact of specific activity in mice with intraperitoneal ovarian cancer | |
dc.type | Journal article | |
dc.creator.author | Li, Ruth Gong | |
dc.creator.author | Napoli, Elisa | |
dc.creator.author | Jorstad, Ida Sofie | |
dc.creator.author | Bønsdorff, Tina Bjørnlund | |
dc.creator.author | Juzeniene, Asta | |
dc.creator.author | Bruland, Øyvind Sverre | |
dc.creator.author | Larsen, Roy H. | |
dc.creator.author | Westrøm, Sara | |
cristin.unitcode | 185,53,49,12 | |
cristin.unitname | Institutt for kreftforskning | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1922360 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Current Radiopharmaceuticals&rft.volume=14&rft.spage=145&rft.date=2021 | |
dc.identifier.jtitle | Current Radiopharmaceuticals | |
dc.identifier.volume | 14 | |
dc.identifier.issue | 2 | |
dc.identifier.startpage | 145 | |
dc.identifier.endpage | 153 | |
dc.identifier.doi | https://doi.org/10.2174/1874471013666201201102056 | |
dc.identifier.urn | URN:NBN:no-93703 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1874-4710 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/91106/4/0009CRP.pdf | |
dc.type.version | PublishedVersion | |